Mersana Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 123
- Market Cap
- $191.3M
- Website
- http://www.mersana.com
Clinical Trials
28
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (28 trials with phase data)• Click on a phase to view related trials
First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b
- Conditions
- Platinum Resistant Ovarian CancerNon-Small Cell Adenocarcinoma
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Mersana Therapeutics
- Target Recruit Count
- 142
- Registration Number
- NCT06517485
- Locations
- 🇺🇸
University of Oklahoma, Oklahoma City, Oklahoma, United States
First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b
- Conditions
- Non Small Cell Lung Cancer MetastaticPlatinum Resistant Ovarian Cancer
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Mersana Therapeutics
- Target Recruit Count
- 62
- Registration Number
- NCT06517433
- Locations
- 🇺🇸
University of Oklahoma, Oklahoma City, Oklahoma, United States
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
- Conditions
- HER2-positive Non-Small Cell Lung CancerHER2-positive TumorsHER2 Low Breast CancerHER2-positive Gastric CancerHER2-positive Colorectal CancerHER2-positive Breast Cancer
- Interventions
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Mersana Therapeutics
- Target Recruit Count
- 162
- Registration Number
- NCT05514717
- Locations
- 🇺🇸
AdventHealth Celebration, Celebration, Florida, United States
🇺🇸Emory Healthcare, Emory Clinic, Atlanta, Georgia, United States
🇺🇸The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
A Study of XMT-1660 in Participants With Solid Tumors
- Conditions
- Triple Negative Breast CancerEndometrial CancerFallopian Tube CancerBreast CancerOvarian CancerAdenoid Cystic CarcinomaPrimary Peritoneal Cavity Cancer
- Interventions
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Mersana Therapeutics
- Target Recruit Count
- 319
- Registration Number
- NCT05377996
- Locations
- 🇺🇸
UC Irvine Health-Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸UCLA, Santa Monica, California, United States
Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)
- Conditions
- Fallopian Tube CancerPrimary Peritoneal CancerHigh Grade Serous Ovarian Cancer
- Interventions
- Other: PlaceboDrug: Upifitimab rilsodotin
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Mersana Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT05329545
- Locations
- 🇺🇸
HonorHealth Research Institute - HonorHealth VGPCC Biltmore, Phoenix, Arizona, United States
🇺🇸The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸University of California Los Angeles, Gynecologic Oncology Clinic, Los Angeles, California, United States
- Prev
- 1
- 2
- 3
- Next
News
FDA Grants Fast Track Designation to Mersana's Emiltatug Ledadotin for Expanded Breast Cancer Treatment
• The FDA has granted Fast Track designation to Mersana's Emiltatug Ledadotin (XMT-1660) for advanced or metastatic HER2-low or HER2-negative breast cancer, including triple-negative breast cancer. • This designation applies to patients who have previously received a topoisomerase-1 inhibitor ADC and, if hormone-receptor positive, have received or are ineligible for endocrine therapy. • Phase 1 trial data shows Emiltatug Ledadotin demonstrates promising efficacy and a favorable safety profile, particularly in heavily pre-treated triple-negative breast cancer patients. • The WHO has approved emiltatug ledadotin (Emi-Le) as the international nonproprietary name (INN) for XMT-1660, marking a significant step in its global recognition.
Emiltatug Ledadotin (XMT-1660) Shows Promise in Phase 1 Trial, Receives FDA Fast Track for Advanced Breast Cancer
Mersana Therapeutics' Emiltatug Ledadotin (XMT-1660) demonstrates a favorable safety profile in a Phase 1 trial with no Grade 4 or 5 treatment-related adverse events.
Merus' Petosemtamab and Mersana's Emi-Le Show Promise in Cancer Treatment
Merus' petosemtamab demonstrates a 36% overall response rate in recurrent/metastatic head and neck squamous cell carcinoma, with median overall survival of 11.4 months.